8:01 AM ET
10-Q
Financial Results
Vor Biopharma Q3 2026 Results: Net Loss of $86.7M, Loss Narrows
Vor Biopharma Inc. is a clinical-stage biotechnology company that remains pre-revenue, incurring significant net losses since inception. The company is focused on the development of its lead product candidate, telitacicept, and expects to require substantial additional funding to support ongoing research and clinical trials.
- Key figure
- Net loss $86.7M